ClinicalTrials.gg
Not yet recruitingNCT07587450NACACUpdated May 22, 2026

Efficacy of Non Operative Treatment With Amoxicillin/Clavulanic Acid Versus Surgical Treatment in Acute Uncomplicated Appendicitis in Children

A Phase 3 interventional study of Amoxi Clavulanate and appendicectomy in Acute Uncomplicated Appendicitis, sponsored by University Hospital, Toulouse. Not yet recruiting at 10 sites in France. Open to participants aged 5 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by University Hospital, Toulouse · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
724
Allocation
Randomized
Ages
5 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Appendicitis with a site in France — 7 open to participants now, 7 under way, 2 of them phase 3. Appendicitis · France.

Planned enrollment
5th of 13
724 · median 473
Started
2026
with 2 others
Phase 3
3 of 18
2 open now
Registered
17th of 18
by date

Among the 18 studies in Appendicitis with a site in France, this one is the 5th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 3, and was the 17th registered.

Appendicitis

421 studies on the registry are indexed under Appendicitis; 67 are open to participants now.

Browse Appendicitis studies →

Open to participants now

7 of the 18 studies in Appendicitis with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 39 Appendicitis studies recruiting now, 18 (46%) set no upper age limit and 19 (49%) stop at 75 or younger; 23 take children under 18; 7 take healthy volunteers.

This study: 5 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Appendicitis with a site in France, or all of them as a file.
02

Study summary

The majority of children with uncomplicated acute appendicitis may be considered for either a non-operative or an operative management. The antibiotic-first strategy appears effective as an initial treatment in 97% of children with uncomplicated AA (recurrence rate 14%), with Non Operative Treatment (NOT) also leading to less morbidity, fewer disability days, and lower costs than surgery. In this trial, the investigators will compare children randomised in a surgery group with children randomised in a NOT group (antibiotic strategy group). Children have 2 on-site visits (including surgery) in the first 12 days with recording of clinical datas and questionnaires, a phone visit at month 1, month 6, month 12 to collect concomitant treatment, Adverse Event (AE) and complications and parental questionnaires at the end of the study. A Cost-Utility analysis will be performed from the healthcare payer's perspective. The time horizon of the medico economic analysis was one year.

Read the detailed description

The design of the NACAC study is an open-label, randomized, multicenter controlled non-inferiority trial with 2 parallel groups: one group of patients will have appendectomy (ST), and the other group will receive antibiotic treatment (NOT).

Children in the non-operative treatment group will be hospitalised for clinical monitoring with initiation of antibiotic therapy at day 1 with Amoxicillin/clavulanic acid IntraVeinous (IV) in 2 doses daily for a minimum of 24 hours and a maximum of 48 hours with a relay of Amoxicillin/clavulanic acid Per Os (PO) in 2 doses daily, for a total of 7 days (IV and PO).

Children can be discharged from hospital after day 1 if the clinical conditions are safe.

In case of hypersensitivity to antibiotic administered the patient will be withdrawn from the study.

Children randomised to the Surgical Treatment group will be hospitalised for a surgical usual management within 24 hours, according to the surgical unit organisation.

For all patients a physical examination (same as inclusion) will be made by an investigator at Day 1 and discharge. Questionnaires will be assessed at D1 and discharge. At discharge, parental absenteism will be evaluated. For ST group, possible post-operative complication will also be evaluated. A visit on the investigator site from Day 10 to Day 15 : all the patients will have a complete physical examination (same as inclusion), child activity evolution and parental absenteeism will be evaluated.

An abdominal ultrasound or CT scan will be performed in patients randomized in the non-operative treatment group. AE and concomitant treatment will be assessed at this study visit by questioning, during the physical examination of the patient.

Compliance to study treatment will be reviewed at day 12 in the NOT group. For ST group, possible post-operative complication will also be evaluated.

At Month 1 (D30), Month 6 (M6) and Month 12 (M12) investigator will realize phone visits in order to :

Get safety aspects related to antibiotic treatment and treatment-related failures at month 1, six months and one year, notably, secondary surgery and in ST group, a complication requiring anew general anaesthesia or possible post-operative complication, will be recorded.

Child activity evolution and parental absenteeism will also be recorded. AE and concomitant treatment will be recorded. A Cost-Utility analysis will be performed from the healthcare payer's perspective.This medico anlysis will need Direct medical costs collection based on security social system.

03

Conditions studied

  • Acute Uncomplicated Appendicitis

Browse trials for

Keywords

  • surgery
  • antibiotics therapy
  • medico - economic analysis
04

Who can participate

Ages eligible
5 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age from 5 to \<15 years-old
  • Diagnosis of first episode of acute uncomplicated appendicitis confirming the diagnosis:
  • an increase in the calibre of the appendix, measured at more than 6 mm in diameter and non-compressibility
  • free fluid, echogenic fat, regional hyperemia
  • performed in hospital or reviewed by local radiologist investigators if performed outpatient.
  • Surgery expected within 24 hours after diagnosis
  • Parental good understanding of the monitoring French instructions
  • Free and , signed by both holders of parental authority/legal representative, with the accord of the minor patient.
  • Affiliation to the health insurance plan

Exclusion criteria

Exclusion Criteria:

  • Ultrasound or CT scan showing one or several stercoliths, a plastron, an abscess or peritonitis
  • Non-visualization of the appendix at ultrasound or CT scan
  • Situations contraindicating surgery or anesthesia (patient for whom surgery and anesthesia would pose a life-threatening risk)
  • Patients who have already received antibiotic therapy for acute appendicitis
  • Known immunodepression, ongoing treatment, diabetes
  • Severe hematologic disorders (such as bone marrow failure, blood clotting disorders)
  • History of proved allergy to Penicillin

    • History of proved allergy to amoxicillin and/or clavulanic acid
    • History of a severe immediate reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam).
    • History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid
    • History of allergy to any of the listed in section 6.1 of each SmPC.
  • On going antibiotherapy : previous antibiotherapy have to be stopped at least 48h before inclusion
  • Parental refusal of research protocol
  • Impossibility of home follow-up after discharge from hospital
  • Pregnancy/ breastfeeding
  • Simultaneously participation in another research study involving medicinal products
  • Mental state rendering the person giving consent incapable of understanding the trial
  • Parents being a relative of the investigator or a relative of someone from the team directly involved in the trial, including assistant doctors, pharmacists, nurses, and trial coordinators
  • Renal insufficiency with \< 30mL/min
  • Presence of an appendicolith
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
724 participants (estimated)

Study arms

  • Experimental
    Non Operative Treatment Group

    Children randomised in this group are treated by antibiotic therapy : 80mg/kg/day of amoxicillin for patients weighing less than 40 kg and 3 g/day for those weighing 40 kg or more)with a relay of Amoxicillin/clavulanic acid (80mg/kg/day for patients weighing less than 40 kg and 3 g/day for those weighing 40 kg or more) PO in 2 doses daily, for a total antibiotictreatment (IV and PO) of 7 days.

    Drug: Amoxi Clavulanate

  • Other
    Surgery Treatment Group

    Children randomised in this group the child will undergo appendectomy within 24 hours, according to surgical unit organization. No antibiotics will be administered before surgery.

    Procedure: appendicectomy

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of treatment-related failures at one year

    readmissions for suspicion of appendicitis, secondary surgery, emergency visits related to appendicitis management, postoperative infections, side effects of antibiotics, adverse events of anesthesia. In surgery group, a normal appendix based on pathology or a complication requiring a new general anaesthesia

    Time frame: 12 months

Secondary outcomes

  1. Initial success rate

    Time frame: Day 12

  2. Score of quality of life with the questionnaire EQ-5D-Y-3L for children

    0 is the worst score and 1 the better score (it is possible to have very bad values under 0)

    Time frame: Day 1, Month 1 and Month 12.

  3. Score of of quality of life with the questionnaire EQ-5D-5L for parents

    0 is the worst score and 1 the better score (it is possible to have very bad values under 0)

    Time frame: Day 1, Month 1 and Month 12.

  4. Direct Medical costs, and indirect costs (parental absenteeism) descriptions

    Time frame: Month 12

  5. Rehospitalization, appendectomy

    Using consumption data available in SNDS database, describe child care pathways over 5 years

    Time frame: from Day 1 to Year 5

  6. Incidence of adverse events

    in the two groups, and incidence of adverse events due to antibiotics in the NOT group

    Time frame: At Month 1 and Month 12

07

Study locations

10 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2029, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 14, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Sep 1, 2029
CompletionEst.
Sep 1, 2034
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07587450
Responsible party
Sponsor
First posted
May 14, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 1, 2029 (estimated)
Completion
Sep 1, 2034 (estimated)
Last update
May 22, 2026

Study contacts

Nadège ALGANS
Contact
algans.n@chu-toulouse.fr
0561777204
Olivier ABBO
study director · University Hospital of Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amoxicillin-Potassium Clavulanate Combination

Start the discussion